Skip to main content
BLFS
NASDAQ Industrial Applications And Services

BioLife Sets October 5 Vote on $1.5B Repligen Merger; $59M Termination Fee Disclosed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$35.25
Mkt Cap
$1.724B
52W Low
$17.86
52W High
$38.1
52W Position info
97% above low
Off High info
7.5% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

BLFS sits 97% above its 52-week low of $17.86 on light trading volume (0.3× avg).

Summary

BioLife Solutions filed its definitive proxy for the Repligen merger, scheduling a stockholder vote for October 5, 2026. The filing discloses a $59M termination fee, executive golden parachutes, and confirms the $31.00 per share consideration.


Key Events · M&A and Partnerships · BLFS

  • Special Meeting Set for October 5

    Stockholders of record as of September 3, 2026 (48,923,333 shares outstanding) will vote on the Repligen merger at a virtual special meeting on October 5, 2026.

  • Merger Consideration Confirmed

    Each BioLife share converts to $11.25 cash plus 0.1442 Repligen shares. At Repligen's September 2, 2026 close of $172.94, the implied value is $36.19 per BioLife share — above the $31.00 deal price at announcement.

  • $59M Termination Fee

    BioLife must pay Repligen $59 million if the deal terminates under specified circumstances, including a superior proposal or change of board recommendation.

  • Executive Golden Parachutes

    CEO Roderick de Greef could receive $28.9 million in merger-related compensation, including $26.1 million in accelerated equity. Total for all five named executive officers is approximately $52.2 million.


Analysis · BLFS · Industrial Applications And Services

The definitive proxy statement advances the Repligen acquisition from announcement to actionable vote. Stockholders of record as of September 3, 2026 will vote October 5, 2026 on the $31.00 per share deal ($11.25 cash plus 0.1442 Repligen shares). The filing reveals a $59 million termination fee, Centerview's fairness opinion supporting the price, and golden parachute compensation totaling $28.9 million for CEO Roderick de Greef alone. The HSR waiting period expires September 3, 2026, clearing a key regulatory hurdle. With the implied merger value now $36.19 per share versus the $31.00 deal price, the fixed exchange ratio means BioLife holders capture Repligen's stock appreciation — a meaningful premium to the original announcement.

How filings like this one have moved

In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BLFS was trading at $35.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $17.86 to $38.10. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BLFS - Latest Insights

BLFS
Sep 09, 2026, 5:22 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $34.93
Real-time Price: $34.93 info
Change: $0 (0%) info
Market Cap: $1.709B info
BLFS
Sep 09, 2026, 5:21 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.93
Real-time Price: $34.93 info
Change: $0 (0%) info
Market Cap: $1.709B info
BLFS
Aug 06, 2026, 4:22 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $33.93
Real-time Price: $34.93 info
Change: +$1.00 (+3%) info
Market Cap: $1.709B info
BLFS
Aug 06, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $33.93
Real-time Price: $34.93 info
Change: +$1.00 (+3%) info
Market Cap: $1.709B info
BLFS
Aug 06, 2026, 4:03 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $33.93
Real-time Price: $34.93 info
Change: +$1.00 (+3%) info
Market Cap: $1.709B info